Altrius Capital Management Inc Sells 1,805 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Altrius Capital Management Inc cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,407 shares of the biopharmaceutical company’s stock after selling 1,805 shares during the quarter. Altrius Capital Management Inc’s holdings in Gilead Sciences were worth $5,232,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Manning & Napier Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter valued at about $25,328,000. Legal & General Group Plc raised its holdings in shares of Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after buying an additional 93,068 shares during the last quarter. IRON Financial LLC bought a new position in shares of Gilead Sciences in the third quarter valued at about $830,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after buying an additional 33,162 shares during the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of Gilead Sciences by 127.6% in the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after buying an additional 119,909 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,947 shares of company stock worth $4,968,674. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Piper Sandler lifted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.86.

Gilead Sciences Stock Down 2.7 %

Shares of NASDAQ:GILD traded down $2.45 during trading on Friday, hitting $89.66. 2,120,625 shares of the company’s stock traded hands, compared to its average volume of 7,059,401. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a current ratio of 1.26, a quick ratio of 0.82 and a debt-to-equity ratio of 1.24. The company has a market cap of $111.74 billion, a price-to-earnings ratio of 1,007.67, a price-to-earnings-growth ratio of 2.85 and a beta of 0.17. The company has a 50-day moving average price of $86.49 and a 200-day moving average price of $75.81.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the business posted $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, research analysts forecast that Gilead Sciences, Inc. will post 4.39 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.